Filing Details

Accession Number:
0001019056-17-000676
Form Type:
13D Filing
Publication Date:
2017-08-16 10:00:32
Filed By:
Knight Therapeutics (barbados) Inc.
Company:
Synergy Chc Corp. (OTCBB:SNYR)
Filing Date:
2017-08-16
SEC Url:
13D Filing
Ownership Summary

Please notice the below summary table is generated without human intervention and may contain errors. Please refer to the complete filing displayed below for exact figures.

Name Sole Voting Power Shared Voting Power Sole Dispositive Power Shared Dispositive Power Aggregate Amount Owned Power Percent of Class
Knight Therapeutics (Barbados) Inc 8,923,768 0 17,645,812 0 17,645,812 19.8%
Filing
 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934
(Amendment No. 4)*

SYNERGY CHC CORP.

 

(Name of Issuer)

COMMON STOCK

 

(Title of Class of Securities)

87165D 109

 

(CUSIP Number)

Michel Loustric

The Business Center, Upton, St Michael BB11103 Barbados

(246) 622-1975

 

(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)

AUGUST 9, 2017

 

(Date of Event which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. o

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent.

* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 
         
CUSIP No. 87165D 109   13D   Page 2 of 4 Pages
         
1.   NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

Knight Therapeutics (Barbados) Inc.
   
2.   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(see instructions)
(a)    o
(b)    o
   
3.   SEC USE ONLY
 
   
4.   SOURCE OF FUNDS (see instructions)
 
OO
   
5.   CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)     o    
6.   CITIZENSHIP OR PLACE OF ORGANIZATION
 
Barbados
   
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH   7.   SOLE VOTING POWER
 
8,923,7681
  8.   SHARED VOTING POWER
 
0
  9.   SOLE DISPOSITIVE POWER
 
17,645,812
  10.   SHARED DISPOSITIVE POWER
 
0
11.   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

17,645,812
   
12.   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
(see instructions)    o
   
13.   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

19.8%
   
14.   TYPE OF REPORTING PERSON (see instructions)

CO
   
         
 
         
CUSIP No. 87165D 109   13D   Page 3 of 4 Pages
         

Item 1.  Security and Issuer.

N/A  

 

Item 2.  Identity and Background.

N/A

Item 3.  Source or Amount of Funds or Other Consideration.

N/A

Item 4.  Purpose of Transaction.

Item 4 is hereby amended to add the following:

Voting power with respect to 8,722,044 shares beneficially owned by the Reporting Person has been appointed to Jack Ross in accordance with the Revised Irrevocable Proxy to Vote Stock of Synergy CHC Corp dated August 9, 2017.

Item 5.  Interest in Securities of the Issuer.

(a)   Amount beneficially owned: 17,645,812 which represents 19.8% of the class
       
(b)   Number of shares as to which the person has:  
       
    (i)

Sole power to vote or to direct the vote: 8,923,7681

       
    (ii)

Shared power to vote or to direct the vote: 0

       
    (iii)

Sole power to dispose or to direct the disposition of: 17,645,812

       
    (iv) Shared power to dispose or to direct the disposition of: 0
       
(c)  

N/A

 

Item 6.  Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer.

 

See Item 4.

 

Item 7.  Material to Be Filed as Exhibits.

       

N/A

 

 

1The Reporting Person has voting power with respect to 8,923,768 shares. Voting power with respect to 8,722,044 shares beneficially owned by the Reporting Person has been appointed to Jack Ross in accordance with the Revised Irrevocable Proxy to Vote Stock of Synergy CHC Corp dated August 9, 2017.

 
         
CUSIP No. 87165D 109   13D   Page 4 of 4 Pages
         

SIGNATURE

 

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

   
  COMPANY NAME
   
  /s/ Michel Loustric
 

Insert Name

   
President
 

Insert Title

   
  08/16/2017
 

Insert Date